Elliot Wilbur
Stock Analyst at Raymond James
(1.31)
# 3,242
Out of 4,829 analysts
55
Total ratings
35.56%
Success rate
-3.54%
Average return
Main Sectors:
Stocks Rated by Elliot Wilbur
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADMA ADMA Biologics | Maintains: Strong Buy | $25 → $32 | $19.98 | +60.16% | 8 | May 8, 2025 | |
| ANIP ANI Pharmaceuticals | Maintains: Outperform | $81 → $83 | $66.30 | +25.19% | 12 | Sep 18, 2024 | |
| SLGL Sol-Gel Technologies | Downgrades: Outperform | $60 → $40 | $7.85 | +409.55% | 8 | Aug 19, 2024 | |
| OGN Organon & Co. | Initiates: Outperform | $33 | $8.71 | +278.87% | 1 | Mar 16, 2023 | |
| PRGO Perrigo Company | Maintains: Outperform | $42 → $43 | $27.01 | +59.20% | 6 | Mar 6, 2023 | |
| PYPD PolyPid | Downgrades: Outperform | $450 → $120 | $2.78 | +4,216.55% | 3 | Sep 6, 2022 | |
| VTRS Viatris | Downgrades: Market Perform | n/a | $8.77 | - | 3 | Mar 1, 2022 | |
| TEVA Teva Pharmaceutical Industries | Downgrades: Market Perform | n/a | $16.93 | - | 4 | Oct 28, 2021 | |
| ZTS Zoetis | Downgrades: Market Perform | n/a | $159.27 | - | 4 | Jul 16, 2021 | |
| ELAN Elanco Animal Health | Initiates: Market Perform | n/a | $11.96 | - | 1 | Jan 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $6.88 | - | 2 | Jan 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $24.18 | - | 3 | Nov 9, 2017 |
ADMA Biologics
May 8, 2025
Maintains: Strong Buy
Price Target: $25 → $32
Current: $19.98
Upside: +60.16%
ANI Pharmaceuticals
Sep 18, 2024
Maintains: Outperform
Price Target: $81 → $83
Current: $66.30
Upside: +25.19%
Sol-Gel Technologies
Aug 19, 2024
Downgrades: Outperform
Price Target: $60 → $40
Current: $7.85
Upside: +409.55%
Organon & Co.
Mar 16, 2023
Initiates: Outperform
Price Target: $33
Current: $8.71
Upside: +278.87%
Perrigo Company
Mar 6, 2023
Maintains: Outperform
Price Target: $42 → $43
Current: $27.01
Upside: +59.20%
PolyPid
Sep 6, 2022
Downgrades: Outperform
Price Target: $450 → $120
Current: $2.78
Upside: +4,216.55%
Viatris
Mar 1, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $8.77
Upside: -
Teva Pharmaceutical Industries
Oct 28, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $16.93
Upside: -
Zoetis
Jul 16, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $159.27
Upside: -
Elanco Animal Health
Jan 10, 2020
Initiates: Market Perform
Price Target: n/a
Current: $11.96
Upside: -
Jan 17, 2019
Upgrades: Market Perform
Price Target: n/a
Current: $6.88
Upside: -
Nov 9, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $24.18
Upside: -